Cantor Fitzgerald Predicts Kura Oncology FY2026 Earnings

Kura Oncology, Inc. (NASDAQ:KURA) – Investment analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for Kura Oncology in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst L. Watsek anticipates that the company will earn ($2.44) per share for the year. Cantor Fitzgerald has a “Strong-Buy” rating on the stock. The consensus estimate for Kura Oncology’s current full-year earnings is ($2.44) per share.

Other analysts also recently issued research reports about the company. JMP Securities reiterated a “market outperform” rating and issued a $28.00 price objective on shares of Kura Oncology in a research report on Wednesday, June 4th. Wedbush reiterated an “outperform” rating and issued a $36.00 price objective on shares of Kura Oncology in a research report on Tuesday, April 8th. Barclays lowered their price objective on Kura Oncology from $32.00 to $11.00 and set an “overweight” rating for the company in a research report on Friday, May 2nd. Mizuho lowered their price objective on Kura Oncology from $32.00 to $30.00 and set an “outperform” rating for the company in a research report on Monday, May 19th. Finally, UBS Group lowered their price objective on Kura Oncology from $27.00 to $14.00 and set a “buy” rating for the company in a research report on Thursday, March 6th. Four investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, Kura Oncology currently has an average rating of “Moderate Buy” and an average price target of $24.50.

Kura Oncology Stock Up 1.6%

Shares of KURA opened at $6.92 on Tuesday. The firm has a market cap of $599.10 million, a P/E ratio of -2.93 and a beta of 0.40. The stock has a 50 day simple moving average of $6.11 and a two-hundred day simple moving average of $7.58. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. Kura Oncology has a 1 year low of $5.41 and a 1 year high of $23.48.

Kura Oncology (NASDAQ:KURA) last issued its earnings results on Thursday, May 1st. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.15). The business had revenue of $14.11 million during the quarter, compared to analyst estimates of $39.08 million.

Hedge Funds Weigh In On Kura Oncology

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Rhumbline Advisers raised its holdings in shares of Kura Oncology by 5.2% during the first quarter. Rhumbline Advisers now owns 105,206 shares of the company’s stock valued at $694,000 after acquiring an additional 5,215 shares in the last quarter. Strs Ohio bought a new position in shares of Kura Oncology during the first quarter valued at approximately $143,000. Acadian Asset Management LLC bought a new position in shares of Kura Oncology during the first quarter valued at approximately $2,180,000. Teza Capital Management LLC bought a new position in shares of Kura Oncology during the first quarter valued at approximately $162,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Kura Oncology by 6.3% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 50,008 shares of the company’s stock valued at $333,000 after acquiring an additional 2,977 shares in the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.